doi: 10.1016/j.lfs.2022.121326 110
Clinical Evidence Behind Approval The FDAs decision to approve Zepbound was based on two large, randomized, double-blind, placebo-controlled studies involving adults with moderate to severe OSA
Another positive finding was seen in 60 patients with BED and T2DM when dulaglutide, which is not currently licensed for obesity, was compared with placebo at 12 weeks 222
If hunger persists despite adequate smoothie nutrition, discuss it with your provider, as it may indicate a need for dose adjustment
All this is to say: If you find that your morning brew worsens your symptoms, try drinking it after food or switching to a lower-acid variety
Written by Amanda Bates, RN and medically reviewed by Dr